Panion’s very first inlicensed asset will be the animal health application of CombiGene AB’s epilepsy project.

However, Panion’s business strategy extends beyond just developing and commercializing a treatment against canine epilepsy and includes the acquisition and inlicensing of other, similar assets. With similar assets is meant the commercialization rights for animal health applications of ongoing human health development projects or products.

By this strategy, considerable synergies are achieved, Panion’s capacity will be used in an optimal way, and the licensors and partners will be offered a convenient way to develop these otherwise unexploited assets.